clinical trial · NCT04655677
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
Peking Union Medical College Hospital·phase1·completed·n = 10
B-cell Non-Hodgkin's LymphomaPrizloncabtagene Autoleucel
brief summary
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.
started
Oct 30, 2020
primary completion
Feb 28, 2024
completion
Jun 30, 2024
last updated
May 23, 2025
detailed description
The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Baseline testing, Lymphodepleting, C-CAR039 infusion, and Follow-up Visit.
official title
A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol